Senile plaques are mainly composed of β‐amyloid (Aβ) peptides,[2] which are generated through the sequential cleavage of amyloid precursor protein (APP) by β‐ and γ‐secretases.[3, 4] Therefore, reducing Aβ production is a potential strategy for AD treatment. Here, APP is linked to Alzheimer disease.